(Q42219509)

English

Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters

scientific article published on 9 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

11

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Andrés Duarte-Rojo

object named as

Andres Duarte-Rojo

8

0 references

9

object named as

Michael P Manns

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Heiner Wedemeyer

5

object named as

Heiner Wedemeyer

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Adriaan J van der Meer

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Giovanna Fattovich

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jordan J Feld

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jean-François Dufour

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Frank Lammert

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Donatella Ieluzzi

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

W Peter Hofmann

12

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Robert J de Knegt

13

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Bart J Veldt

14

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Harry L A Janssen

15

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

9 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

322-331

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A review of the treatment of chronic hepatitis C virus infection in cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A simulation study of the number of events per variable in logistic regression analysis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Simplifying a prognostic model: a simulation study based on clinical data

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Survival model predictive accuracy and ROC curves

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A prognostic model for predicting survival in cirrhosis with ascites.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Prognosis and life expectancy in chronic liver disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

A model to predict survival in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Model for end-stage liver disease (MELD) and allocation of donor livers

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Validation of model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Progression of fibrosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Alcohol-related cirrhosis--early abstinence is a key factor in prognosis, even in the most severe cases

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Brief communication: clinical implications of short-term variability in liver function test results

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Prognostic Value of Child-Turcotte Criteria in Medically Treated Cirrhosis

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305357

21 January 2018

Identifiers

10.1136/GUTJNL-2013-305357

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42219509&oldid=1936218116"